Stage III Colon Cancer: What Works, What Doesn't and Why, and What's Next.
Adjuvant treatment for patients with stage III colon cancer, one of the most common malignancies, is an important issue in oncology. The use of adjuvant chemotherapy in this setting has undoubtedly improved prognosis. This article describes the development of adjuvant therapy and progress in the past decade as well as failures in multiple agents that have demonstrated efficacy in the metastatic setting. Finally, the current clinical trials will be reviewed, as well as complementary therapies including diet and exercise for survivors of colorectal cancer.
From the Service d'Oncologie Médicale, Hôpital Saint-Antoine, Assistance Publique des Hôpitaux de Paris, Paris, France and Université Pierre et Marie Curie (Paris 6); University of North Carolina, Chapel Hill, NC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Thierry
T
André
From the Service d'Oncologie Médicale, Hôpital Saint-Antoine, Assistance Publique des Hôpitaux de Paris, Paris, France and Université Pierre et Marie Curie (Paris 6); University of North Carolina, Chapel Hill, NC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Bert H
BH
O'Neil
From the Service d'Oncologie Médicale, Hôpital Saint-Antoine, Assistance Publique des Hôpitaux de Paris, Paris, France and Université Pierre et Marie Curie (Paris 6); University of North Carolina, Chapel Hill, NC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Jeffrey A
JA
Meyerhardt